The Phase 1 Trial of Takeda's TAK-861 Among Healthy Men Shows Potential for Increasing Wakefulness.

Published Date: 02 Nov 2023

In a recent study, the orexin-type 2 receptor agonist TAK-861 was evaluated at high and low dosages. The results showed improvements in wakefulness when compared to a placebo in healthy adult men.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers find distinct cell receptors with the potential for new treatments.

2.

Breast cancer patients' arms swell less after an effective lymph node transfer.

3.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

4.

Too Many Chest CTs for Incidental Lung Nodules?

5.

Global warming could be driving up women's cancer risk, find researchers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot